Creative Medical Technology Holdings, Inc.
CELZ · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.03 | -0.01 | 0.03 |
| FCF Yield | -16.94% | -37.03% | -51.11% | -22.84% |
| EV / EBITDA | -0.24 | 2.08 | 1.15 | 1.79 |
| Quality | ||||
| ROIC | -18.51% | -20.56% | -29.67% | -16.89% |
| Gross Margin | 0.00% | 60.00% | 60.00% | 0.00% |
| Cash Conversion Ratio | 0.95 | 0.94 | 0.97 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -37.52% | -56.64% | -42.49% | -50.11% |
| Free Cash Flow Growth | 27.19% | 18.36% | -97.80% | 32.92% |
| Safety | ||||
| Net Debt / EBITDA | 5.44 | 4.72 | 3.24 | 5.78 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 30.93 | 1.21 | 0.55 | -17.25 |
| Cash Conversion Cycle | -768.36 | -20,339.93 | -20,350.20 | 415.70 |